Amsterdam Molecular Therapeutics (AMT) Holding B.V. is a biopharmaceutical company that develops gene-based therapies for orphan diseases.
Initial Public Offering
Offering of up to 5,000,000 new ordinary shares.
Trading on Eurolist by Euronext is expected to commence on or about 20 June 2007. Settlement date is the third business day following the listing date, expected to be on or about 25 June 2007